title: Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells.
abstract: BACKGROUND
  The clinical efficacy of combination therapy comprising a long acting beta(2)-agonist (LABA) and corticosteroid is widely recognized for the treatment of adult asthma. Here we examine the effect of salmeterol xinafoate (SX) and fluticasone propionate (FP) alone and in combination on the immunological activation of human cultured mast cells (HCMC)in vitro.
  
  
  METHODS
  HCMC were passively sensitized with IgE antibody and then activated by challenging with anti-IgE antibody. The effect of drugs on the activation of mast cells was examined by measuring the amount of released chemical mediators (histamine, leukotrienes (LT) and prostaglandin D(2) (PGD(2))) and granulocyte macrophage colony stimulating factor (GM-CSF).
  
  
  RESULTS
  The release of each chemical mediator was inhibited by 10-9-10-8M SX but not by 10-10-10-7M FP. The production of GM-CSF was inhibited by a concentration of 10-8M in both drugs and the inhibition was augmented by combined treatment with 10-11M of each drug.
  
  
  CONCLUSIONS
  The immunological release of chemical mediators (histamine, LT, PGD(2)) from HCMC was inhibited by SX but not by FP. SX and FP inhibited the production of GM-CSF by HCMC and both drug showed synergistic inhibition in the production of GM-CSF.
authors.affiliation: Department of Pharmacology, Gifu Pharmaceutical University, Japan.
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Akabane
authors.forename: Masayuki
authors.initials: M
authors.lastname: Murata
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kubota
authors.forename: Eiji
authors.initials: E
authors.lastname: Takashima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Naoki
authors.initials: N
authors.lastname: Inagaki
authors.forename: Michiaki
authors.initials: M
authors.lastname: Horiba
authors.forename: Hiroichi
authors.initials: H
authors.lastname: Nagai
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000730:Androstadienes / Q000008:administration & dosage / Q000494:pharmacology*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D000068298:Fluticasone; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D015289:Leukotrienes / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D015230:Prostaglandin D2 / Q000378:metabolism; D000068299:Salmeterol Xinafoate
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D015289:Leukotrienes; D007073:Immunoglobulin E; D000068299:Salmeterol Xinafoate; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000068298:Fluticasone; D000420:Albuterol; D015230:Prostaglandin D2